Karo Pharma, an EQT VIII portfolio company, has announced the acquisition of the remaining European rights to the Pevaryl brand portfolio from Cilag GmbH International, an affiliate of Johsnon & Johnson.
The acquisition consolidates the full ownership of the Peravyl brand portfolio with Karo Pharma. The portfolio generated net sales of approximately €20M in 2019.
Karo Pharma already commercializes and owns Gyno-Pevaryl , Epi – Pevaryl and Pevaryl in certain European markets.
The brand portfolio is available in more than 20 European countries with €30M in net sales. This acquisition adds scale and scope in new regions such as Italy as well as focus categories of intimate care and foot care.
Source: Karo Pharma
